Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + tislelizumab + CAPOX versus tislelizumab + CAPOX as first-line treatment for HER2-low/intermediate advanced gastric or gastroesophageal junction adenocarcinoma
CTR20251315Phase 3Active
- Sponsor
- RemeGen
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapoxetine, tislelizumab, oxaliplatin, capecitabine in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Started May 2025; status: active.
02
Drugs
dapoxetinetislelizumaboxaliplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20251315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251315.